The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Next-generation ALK inhibitors: treatment sequencing and resistance
Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, reflects on next-generation ALK inhibitors in non-small cell lung cancer, highlighting the importance of treatment sequencing given the availability of different ALK inhibitors, as well as potential methods to mitigate the development of resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
